

EVALUATION OF ANTI-*Schistosoma mansoni* IgG ANTIBODIES IN PATIENTS WITH CHRONIC SCHISTOSOMIASIS MANSONI BEFORE AND AFTER SPECIFIC TREATMENT

Célia Maria V. VENDRAME(1), Márcia Dias T. CARVALHO(2), Célia Regina F. YAMAMOTO(3), Maria Cristina NAKHLE(1), Silvino Alves CARVALHO(1) & Pedro Paulo CHIEFFI(1,4)

SUMMARY

The circumoval precipitin test (COPT), enzyme-linked immunosorbent assay (ELISA) and the immunoblotting anti-adult worm antigen (AWA) and soluble egg antigen (SEA) tests were applied to 17 chronically schistosome-infected patients for the detection of anti-*Schistosoma mansoni* antibodies before and on four occasions after oxamniquine administration over a period of six months. Compared to a control group, schistosomiasis patients showed high levels of IgG antibodies in AWA and SEA-ELISA. A decrease in IgG levels was observed six months after treatment, although negative reactions were not obtained. Significant decreases in IgG₁, IgG₃ and, mainly, IgG₄, but not anti-SEA IgG₂ levels were observed six months after treatment, again without negativity. Analysis of anti-AWA IgG antibodies by immunoblotting before treatment showed a 31 kDa strand in 14 patients (82%) which disappeared in three cases up to six months after treatment; furthermore, anti-SEA IgG antibodies showed the same band in nine patients (53%) before treatment, which disappeared in only four cases up to six months after treatment.

KEYWORDS: Schistosomiasis diagnosis; Schistosomiasis cure evaluation; Immunoenzymatic tests; Immunoblotting.

INTRODUCTION

In Brazil there are at least 2,500,000 individuals infected with *Schistosoma mansoni* and about 25 millions live in areas where the transmission of this helminthiasis may be possible³². The laboratory diagnosis of active schistosomiasis mansoni is made principally by the finding of *S. mansoni* eggs in the stool⁹. However, fecal parasitologic tests are not considered to have high sensitivity because of factors such as irregularity in *Schistosoma* egg shedding^{3,8}, absence of egg laying just after anti-schistosome treatment even if not successful and tissue egg retaining due to intestinal fibrosis²⁹. Thus, several immunological tests using crude or purified egg and adult worm antigens have been developed in the last decades to detect anti-*S. mansoni* antibodies and some of them have been proposed for treatment evaluation.

The circumoval precipitin test (COPT) is one of the exams used for the diagnosis of schistosomiasis and for the evaluation of anti-schistosome treatment³¹ and consists of immune complex formation around schistosome eggs incubated with serum from schistosome-infected individuals. It is considered as a highly sensitive and specific test and usually becomes non-reactive from 6 to 12 months after anti-schistosome treatment^{14,33}. However, in some instances, patients continue to have positive COPT results after specific anti-schistosome treatment or test negativity occurs only a long time after treatment¹⁶.

Immunoenzymatic tests for anti-*S. mansoni* antibodies utilize antigens obtained from either adult worms or eggs. Some of these tests show a decrease in anti-schistosome antibody levels soon after specific treatment³⁴, while others show the persistence of high antibody levels up to 18 months¹⁰. When IgG subclasses are analyzed there is a decrease in all subclasses, with special relevance in the case of IgG₄².

Immunoblotting tests have been used to detect AWA antibodies since an immunogenic fraction with a molecular weight of 31-32 kDa (Sm 31/32) was considered to be the most frequently recognized fraction and could therefore be used as a serologic marker^{35,36,43}. Furthermore this fraction became negative or decreased in the serum of treated patients exposed to a low infection risk^{35,36}. On the other hand, KIMURA²² did not obtain the same results.

Using the immunoblotting test for SEA, NOYA *et al.*³⁰ studied a group of patients after therapy and identified a special fraction of about 31 kDa which decreased after specific treatment. This fraction, corresponding to the Omega 1 antigen described by DUNNE *et al.*⁷, was present in a special schistosome egg antigen known as cation exchanging fraction-6 (CEF-6) and has been considered an important diagnostic marker for cure control. Moreover, this antigen is one subcomponent of COPT and has been considered as a very sensitive and specific antigen^{5,27,28}. DOENHOFF *et al.*⁴, employing this antigen as a serologic

(1) Laboratório de Imunopatologia da Esquistossomose (LIM/06) do Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brasil.

(2) Laboratório de Lípidos (LIM/10) do Instituto de Medicina Tropical de São Paulo, FMUSP, São Paulo, Brasil.

(3) Laboratório de Imunologia (LIM/48), do Instituto de Medicina Tropical de São Paulo, FMUSP, São Paulo, Brasil.

(4) Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brasil.

Correspondence to: Pedro Paulo Chieffi, Laboratório de Imunopatologia da Esquistossomose (LIM/06), Instituto de Medicina Tropical de São Paulo. Av. Dr. Enéas de Carvalho Aguiar 500, 2º andar, 05403-000 São Paulo, SP, Brasil. Fone/Fax: +55-11-3064-5132. E-mail: pchieffi@usp.br

marker, observed 50% and 80% negative reactions in schistosomiasis patients from Santa Lucia, West Indies, six and 12 months after treatment, respectively. However, a similar evaluation of patients from Puerto Rico did not show the same results^{6,15}.

The occurrence of controversial results when the same immunological technique is used in different populations justifies the evaluation of tests usually employed in the diagnosis and cure control of schistosomiasis under our operational conditions in order to standardize immunological evaluation of schistosomiasis treatment. Furthermore, the decrease of the rate of infection with *S. mansoni* in Brazil, particularly in São Paulo State, strengthens the importance of using an immunological technique of diagnosis rather than parasitological tests in epidemiological surveys.

MATERIAL AND METHODS

Patients and sera: After informed consent, 17 chronically schistosome-infected male and female patients ranging in age from 17 to 77 years (mean age = 33), with either the intestinal or hepatointestinal form of the disease were studied. All of them were migrants from different Brazilian endemic areas for schistosomiasis, living in São Paulo City and admitted to the Hospital das Clínicas, Universidade de São Paulo. During the study they did not return to endemic areas. Blood and fecal samples were taken immediately before and 40, 90, 150 and 180 days after treatment with oxamniquine (15 mg/kg weight). Blood was allowed to clot at room temperature and centrifuged and serum was separated and kept frozen at -20 °C until testing. Diagnosis of schistosomiasis mansoni before and after treatment was performed by the Kato-Katz method²¹, with three microscope slides prepared for each sample. Control sera were obtained from 30 Brazilian blood donor volunteers.

Adult worm antigen (AWA) preparation: Adult *S. mansoni* worms (BH strain) were collected by portal perfusion of infected hamsters with 0.9% sodium chloride solution. Worms were thoroughly washed with PBS and stored at -20 °C. Approximately 12,000 adult male and female worms were thawed, homogenized in saline with 1 mM phenylmethylsulfonyl fluoride (PMSF), disrupted by hand and homogenized with a Potter-Elvehjem apparatus for 1 hour at 4 °C. They were then centrifuged at 26,000 x g for 1 hour at 4 °C using an SW 41 rotor (L-8 ultracentrifuge, Beckman Instruments Inc, Palo Alto, CA, USA).

Soluble egg antigen (SEA) preparation: *S. mansoni* eggs were isolated from liver and intestinal walls of infected hamsters by differential sieving and washed by repeated centrifugation. SEA was prepared as described by BOROS & WARREN¹.

The protein contents of AWA and SEA were determined by the method of LOWRY *et al.*²⁵ using bovine albumin as standard, lyophilized in small aliquots and stored at -70 °C.

Circumoval precipitin test (COPT): This method was performed as previously described by OLIVER-GONZÁLEZ³¹. *S. mansoni* eggs obtained as above were adjusted to a concentration of 50 eggs/10 µL in hypertonic solution, added to 25 µL of patient serum and incubated at 37 °C for 48 hours. The reaction was read under the light microscope according to the criteria described by SPENCER *et al.*⁴⁰, i.e. < 10% of

eggs with circumoval precipitation indicated in a negative reaction and ≥ 10% a positive reaction.

Enzyme-linked immunosorbent assay (ELISA): Polystyrene microtiter plates (Costar, Cambridge, MA, USA) were coated with 50 µL of either AWA or SEA at a protein concentration of 10 µL/mL diluted in PBS supplemented with 0.05 Tween 20 (PBS-T), kept for 2 hours at 37 °C and then for 16 hours at 4 °C. Between the steps of the reaction wells were washed three times with 200 µL of PBS-T for 1 hour at room temperature. Then 50 µL of diluted serum (1:200) were added to the wells and incubated for 1 hour at 37 °C; after this time 50 µL of horseradish peroxidase goat anti-human IgG (SIGMA, Chemical Co., St. Louis, MO, USA; IgG 1:5,000 for AWA and SEA) were added. After incubation for 1 hour at 37 °C, 50 µL of substrate solution were added and 15 minutes after incubation at room temperature the enzymatic reaction was stopped by the addition of 50 µL of 4 N H₂SO₄. Absorbance was read at 492 nm in a Titertek Multiskan MCC/340P, model 2.20 (Labsystems, Finland) and the results were obtained by duplicate readings. Optimal dilutions of the antigen protein concentration for coating the wells and serum and conjugate dilutions were determined previously by checkerboard titration using pooled positive and negative sera. An optical density (OD) greater than the mean plus two standard deviations of the value for 30 healthy Brazilian individuals was considered to be the cut-off point.

ELISA for the anti-SEA IgG subclass: This test was performed with sera obtained before and 180 days after anti-*S. mansoni* treatment. IgG subclass antibodies were detected using a slightly different protocol: 50 µL of serum samples were diluted 1:200 in PBS-Tg and incubated for 16 hours at 37 °C. Mouse monoclonal antibodies specific for each human IgG subclass (SIGMA Chemical Co.): anti-IgG₁ (clone HP-6001), anti-IgG₂ (clone HP-6014), anti IgG₃ (clone HP-6050) and IgG₄ (clone HP-6025) were used at 1:1,000 in blocking buffer. Thereafter, 50 µL of peroxidase-conjugated sheep anti-mouse Ig (SIGMA Chemical Co.) at 1:1,000 dilution in blocking buffer were added for 1 hour at 37 °C. Subsequently the protocol was performed as previously described.

Immunoblotting: Proteins were separated electrophoretically under reducing conditions by one-dimensional SDS-PAGE as described by LAEMMLI²⁴. AWA (215 µg) and SEA (225 µg) were boiled for 3 minutes and applied to the 10% polyacrylamide gel using a Mini Protean II apparatus (Bio-Rad Labs, Hercules, CA, USA). High range molecular weight standards were also obtained from Bio-Rad Labs.

The separated proteins were electrotransferred to NCP using a Trans Blot transfer cell apparatus (Bio-Rad Labs) and 4 mm strips were cut. Non-specific sites were blocked with 0.05% Tween 20 supplemented with 5% non-fat dry milk in PBS adjusted to pH 7.4 (PBS-Tm). Serum diluted at 1:100 in PBS-Tg was added and kept for 1 hour at 37 °C. After washing in PBS-T, the enzymatic conjugate labeled with alkaline phosphatase for human anti-IgG at a previously determined optimal dilution was added and incubated for 2 hours at 37 °C. Then, after another washing, blots were visualized with the enzymatic substrate bromo-chloro-indolyl-phosphate and nitroblue tetrazolium in 1 M Tris (BCIP-NBT) with 4 M sodium chloride, pH 9.5.

The reaction was stopped by washing the strips in distilled water. The strips showing protein recognition by the schistosomiasis patient

sera were scanned using an optical densitometer and measured by analysis of one-dimensional separation and dot blots using an Image Master Program 1.20 produced by Pharmacia Biotech AB.

Statistical analysis: The results are expressed as mean and standard deviation. The ANOVA test with the Student Newman-Keuls contrast post-test was used for statistical analysis of the various groups. The paired and unpaired Student test and Pearson correlation were used for statistical comparison of two groups. A level of confidence of 95% ($p < 0.05$) was considered as significant.

RESULTS

This study was carried out on 17 patients with a parasitological diagnosis of schistosomiasis mansoni made by the Kato-Katz method. Ninety days after treatment with oxamniquine (a single oral dose of 15 mg/kg weight) all patients yielded negative results in fecal exams; the COPT, on the other hand, remained positive in one case (Table 1).

Table 1

Circumoval precipitin test (COPT) applied to 17 chronic schistosomiasis patients before and after specific treatment

Patients	Clinical Form*	Age (year)	Fecal eggs/g of feces V	COPT	
				Before treatment #	180 days after treatment #
1	I	34	96	+	-
2	I	27	192	+	-
3	I	39	2304	-	-
4	I	32	1344	+	-
5	I	29	24	+	-
6	I	31	96	-	-
7	I	32	24	+	-
8	I	26	288	-	-
9	HI	31	120	+	-
10	HI	41	96	+	-
11	I	42	24	-	-
12	I	37	96	ND	ND
13	I	21	432	+	+
14	I	17	2472	+	-
15	I	28	240	+	-
16	I	26	24	-	-
17	HI	77	672	+	-

ND = not determined; * - Clinical form: hepatointestinal (HI) or intestinal (I); V - Counting fecal egg excretion before oxamniquine treatment by the Kato-Katz method²¹. The result is reported as the mean for three slides; # - Positive reaction (+) $\geq 10\%$ of immunoprecipitin around viable eggs.

The immunoenzymatic tests (ELISA) performed with antigens obtained from either adult worms (AWA) or *S. mansoni* eggs (SEA) did not show negative results up to 180 days after treatment. When AWA was used an increase in antibody levels was observed 40 days after treatment, followed by a significant decrease 140 days later, i.e. 180 days after treatment (Fig. 1). Anti-SEA IgG levels were significantly decreased from 90 to 180 days after treatment (Fig. 2).




Fig. 1 - Anti-AWA IgG antibodies detected by ELISA in 17 chronic schistosomiasis patients before and after specific treatment. Cut off = 0.173. ANOVA test with $p < 0.0001$ followed by the Student Newman-Keuls contrast post-test with *** $p < 0.001$, ** $p < 0.01$ and * $p < 0.05$ in relation to pre-treatment. Horizontal bar represents the mean value.




Fig. 2 - Anti-SEA IgG antibodies detected by ELISA in 17 chronic schistosomiasis patients before and after specific treatment. Cut off = 0.208. ANOVA test with $p < 0.0001$ followed by the Student Newman-Keuls contrast post-test with *** $p < 0.001$ in relation to pre-treatment. Horizontal bar represents the mean value.

The anti-SEA IgG₁, IgG₂, IgG₃ and IgG₄ subclasses were determined and significant decreases in IgG₁, IgG₃ and IgG₄ levels but not in IgG₂ were observed (Fig. 3). IgG₄ showed the most significant decrease 180 days after treatment, although the results were still positive.

A heterogenous pattern of reactivity was observed when the immunoblotting for anti-AWA and SEA IgG antibodies of all 17 patients were analyzed before and after 180 days after treatment (Tables 2 and 3). Table 4 shows the percentage of positive bands found in all patients before and 180 days after treatment with oxamniquine.

DISCUSSION

In the present study, 17 schistosomiasis patients, 14 of them harboring moderate or low parasite burdens, living for several years in a non-endemic area for *S. mansoni* infection were examined before and after treatment with oxamniquine. All of them had been considered cured by fecal tests and all but one by COPT in the evaluation carried out six months after treatment (Table 1). In contrast to reports by others^{14,31,33}, under our operational conditions COPT showed a relatively low




Fig. 3 - Anti-SEA subclasses IgG₁, IgG₂, IgG₃, IgG₄ antibodies detected by ELISA in 17 chronic schistosomiasis patients before and after epecific treatment. Horizontal bar represents the mean value. Cut off (IgG₁ = 0.135, IgG₂ = 0.175, IgG₃ = 0.121, IgG₄ = 0.152). Paired Student t test with *p < 0.01, **p < 0.05, ***p < 0.0001 in relation to pre-treatment.

Table 2
Antigenic bands reacting with IgG AWA found in chronic schistosomiasis patients

17 chronically schistosome-infected patients																	
KDa	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
204			xx		xx									xx			
194	xx		x-		xx			xx		xx			xx	xx		xx	
164	xx		xx	xx	-x			xx	xx	xx	xx	xx	xx	xx		xx	
152				xx	xx				xx	xx	xx	xx		xx		xx	
130	xx		xx	xx	xx			xx	xx	xx	xx	xx	xx	xx		xx	
115	xx			xx					xx	xx	xx	xx	xx	xx		xx	
92	xx	xx	xx	xx	xx	xx		xx	xx	xx	xx	xx	xx	xx		xx	xx
67	xx	xx	x-	xx	xx	xx		xx	xx	xx	xx	xx	xx	xx	xx	xx	
55	xx	xx	x-	x-	xx	xx		xx	x-		xx	xx	xx	xx	x-	xx	xx
50	xx	xx	xx	xx	xx	xx		xx	-		xx	xx	xx	xx	xx		xx
40	xx	xx							-		xx	xx		x-			
36	xx	xx	-	x-	-x						xx	xx	xx	x-			
31	xx	xx		xx	x-	xx	xx		xx	x-	xx	xx		x-	xx	-x	xx
25			x-	xx	x-			xx	x-			xx		xx		-	xx
22					xx					-	xx	xx					

The symbols in sequence correspond to the immunoblot reaction for each patient before and 180 days after specific treatment: (x) reacting band and (-) non-reacting band.

Table 3
Antigenic bands reacting with IgG SEA found in chronic schistosomiasis patients

KDa	17 chronically schistosome-infected patients																
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
203			xx														
172						xx	xx			xx	xx	xx	xx			xx	xx
130	xx					x-				xx		x-				xx	xx
110	xx		xx			x-											
92				x-		xx		xx	xx		xx	xx	xx			xx	
73	x-				xx					xx	x-						xx
62		xx	xx	xx	xx			xx	xx	xx	xx	xx	xx	xx		xx	xx
55		xx	xx	xx	xx		xx	xx		xx	xx	xx	xx	xx			xx
50	x-	xx		xx	xx	xx				xx	xx	xx	xx			xx	xx
41	xx				xx		xx		x-	x-	xx		xx	xx	xx	xx	xx
37			xx		xx	xx	x-		x-		xx	x-				xx	
31	x-		xx		xx					x-	xx	xx	xx			x-	xx
25	xx			xx	x-					x-	xx	xx	x-		xx		
22				xx	xx	xx	xx		x-		xx	xx	xx			xx	x-
18							xx			xx	xx		xx			xx	

The symbols in sequence correspond to the immunoblot reaction for each patient before and 180 days after specific treatment: (x) reacting band and (-) nonreacting band.

Table 4

Percent (%) of anti-AWA IgG and anti-SEA IgG protein bands (kDa) in 17 chronically schistosome-infected patients before and after specific treatment

kDa	Anti-AWA % reactive patients		Anti-SEA % reactive patients	
	before treatment	180 days after treatment	before treatment	180 days after treatment
204	18	18	06	06
194	47	41	47	47
164	71	71	35	23
152	47	47	18	12
130	71	71	47	41
115	53	53	29	18
92	88	88	76	76
67	82	76	71	71
55	82	59	65	59
50	82	76	65	53
40	35	23	47	29
36	53	35	53	35
31	82	65	47	29
25	53	29	59	47
22	23	18	29	29

sensitivity before treatment. Of 16 patients submitted to this diagnostic procedure only 11 (68.7%) yielded positive results.

The results of immunological tests (anti-AWA and anti-SEA IgG-ELISA) performed before specific treatment were similar to those obtained by others^{13,26,28,40} and support the usefulness of these techniques for schistosomiasis diagnosis, mainly in areas where the parasite burden is low and consequently fecal tests are less sensitive²⁰.

Forty-days after treatment with oxamniquine anti-AWA IgG-ELISA, but not anti-SEA IgG-ELISA antibodies showed a significant increase (Fig. 1) probably as a consequence of antigen release following worm death^{34,39}. Up to six months after oxamniquine treatment both anti-AWA and anti-SEA IgG antibody levels showed a significant decrease (Fig. 1 and 2), although not reaching the level of non-infected controls.

As also observed by others, the levels of IgG₁, IgG₂, IgG₃ and principally IgG₄ anti-SEA antibodies were significantly higher than those found in non-infected people before oxamniquine treatment^{2,18,19} (Fig. 3). Six months after oxamniquine administration a sharp decrease in IgG₄ levels and a less significant decrease in IgG₁ and IgG₃ levels were observed. These results are in agreement with the assumption of best performance of schistosome egg antigens in the evaluation of specific schistosomiasis treatment, as already pointed out by other investigators^{6,30,42}.

Positive anti-schistosome serological reactions in patients submitted to efficient specific treatment could be explained either by the persistence of some living worms, without oviposition, in the host's portal system⁴⁴ or by the temporary persistence of schistosome antigens in host tissues^{12,41}.

In the 17 patients studied here both anti-AWA and anti-SEA antibody tests resulted positive at least up to six months after oxamniquine administration, indicating that these immunological tests cannot be used for treatment evaluation. However, the greatest decrease in IgG₄ levels verified six months after treatment (Fig. 3) deserves attention. This immunoglobulin subclass has been considered as a relatively good marker for worm burden² and, on the other hand, it has been identified as the first antibody subclass to decrease after anti-*S. mansoni* and anti-*S. haematobium* treatment^{11,33}. According to our results, although showing positive levels six months after oxamniquine administration, the determination of IgG₄ anti-SEA antibodies could be used as a preliminary test for treatment evaluation in schistosomiasis patients.

Analysis of IgG anti-AWA and anti-SEA immunoblottings showed a heterogeneous pattern before and after specific treatment in the 17 patients studied. The bands of 31-32 kDa, considered to be of high diagnostic value^{17,35,36,37}, were found in 82% and 53% of cases, respectively, before treatment when AWA and SEA were analyzed (Tables 2 and 3). This kind of diversity was, in fact, previously pointed out by others in Brazilian schistosomiasis patients: VALLI *et al.*⁴³ found 98% positivity for the 31 kDa band and KIMURA²² found only 12.5% positivity for the same strand.

Although the 31-32 kDa bands have been considered as good markers for schistosomiasis cure after specific treatment by some researchers^{23,38}, in the evaluation performed 180 days after oxamniquine administration these bands vanished in only three cases (Tables 2 and 3), persisting in 65% and 29% of the patients studied when AWA and SEA antigens were used, respectively (Table 4).

In summary, the use of COPT, immunoenzymatic tests as well as the immunoblotting techniques did not permit a safe and definitive early evaluation of schistosomiasis treatment in the 17 patients studied. Thus, the ideal diagnostic method for schistosomiasis cure control seems to be still far from available, but IgG₄ subclass levels showed a significant decrease up to 180 days after specific treatment. Long term post treatment follow-up would be relevant and other studies are necessary to define in further detail the role of IgG₄ and its promising usefulness as a possible cure marker.

RESUMO

Avaliação da presença de anticorpos IgG anti-*Schistosoma mansoni* no soro de pacientes com esquistossomose mansônica crônica, antes e após tratamento específico

Em 17 pacientes com infecção crônica por *Schistosoma mansoni* utilizaram-se os testes de reação periovular, imunoenzimático (ELISA) e imunoblotting, empregando-se antígenos obtidos a partir de vermes adultos (AWA) ou de ovos de *S. mansoni* (SEA), para detecção de anticorpos anti-*S. mansoni*, antes e em quatro ocasiões após tratamento com oxamniquine. Quando cotejados a grupo controle os pacientes esquistossomóticos revelaram altos níveis séricos de anticorpos IgG nos testes ELISA (anti-AWA e anti-SEA), não se observando, porém, negatificação até seis meses após tratamento específico. Encontrou-se, entretanto, decréscimo significativo, sem negatificação, dos níveis de IgG₁, IgG₃ e, principalmente, IgG₄, quando se utilizou antígeno solúvel obtido a partir de ovos de *S. mansoni* (SEA), seis meses após administração de oxamniquine. O mesmo não foi observado no caso de anticorpos da subclasse IgG₂.

Nos imunoblottings efetuados com o emprego de antígeno de verme adulto (AWA), antes do tratamento com oxamniquine, evidenciou-se a presença de banda com 31 kDa em 14 (82%) dos 17 pacientes estudados, observando-se seu desaparecimento em três pacientes examinados seis meses após tratamento específico. Quando se utilizou antígeno obtido a partir de ovos de *S. mansoni* (SEA) a mesma banda foi evidenciada em nove pacientes, desaparecendo em quatro casos, após o tratamento.

REFERENCES

1. BOROS, D.L. & WARREN, K.S. - Delayed hypersensitivity-type granuloma formation and dermal reaction induced and elicited by a soluble factor isolated from *Schistosoma mansoni* eggs. **J. exp. Med.**, 132: 488-507, 1970.
2. BOCTOR, F.N. & PETER, J.B. - IgG subclasses in human chronic schistosomiasis: over-production of schistosome-specific and non-specific IgG4. **Clin. exp. Immunol.**, 82: 574-578, 1990.
3. CHIEFFI, P.P.; MARQUES, R.M. & SIQUEIRA, J.G.V. - Avaliação da eficácia do método de Kato-Katz no diagnóstico parasitológico da esquistossomose mansônica. **Rev. Inst. Adolfo Lutz**, 41: 23-30, 1981.
4. DOENHOFF, M.J.; DUNNE, D.W. & LILLYWHITE, J.E. - Serology of *Schistosoma mansoni* infection after chemotherapy. **Trans. roy. Soc. trop. Med. Hyg.**, 83: 237-238, 1989.
5. DUNNE, D.W.; LUCAS, S.; BICKLE, Q. *et al.* - Identification and partial purification of an antigen (ω_1) from *Schistosoma mansoni* eggs which is putatively hepatotoxic in T cell deprived mice. **Trans. roy. Soc. trop. Med. Hyg.**, 75: 54-71, 1981.
6. DUNNE, D.W.; HILLYER, G.V. & VAZQUEZ, G. - *Schistosoma mansoni* cationic egg antigens (CEF-6): immunoserology with oxamniquine-treated patients and involvement of CEF-6 in the circumoval precipitin reaction. **Amer. J. trop. Med. Hyg.**, 38: 508-514, 1988.
7. DUNNE, D.W.; JONES, F.M. & DOENHOFF, M.J. - The purification, characterization, serological activity and hepatotoxic properties of two cationic glycoproteins (α_1 and ω_1) from *Schistosoma mansoni* eggs. **Parasitology**, 103: 225-236, 1991.
8. ENGELS, D.; SINZINKAYO, E. & GRYSEELS, B. - Day-to-day egg count fluctuation in *Schistosoma mansoni* infection and its operational implications. **Amer. J. trop. Med. Hyg.**, 54: 319-324, 1996.
9. FELDMEIER, H. & POGGENSEE, G. - Diagnostic techniques in schistosomiasis control. A review. **Acta trop. (Basel)**, 52: 205-220, 1993.
10. GAZZINELLI, G.; LAMBERTUCCI, J.R.; KATZ, N. *et al.* - Immune responses during human schistosomiasis mansoni. XI. Immunologic status of patients with acute infections and after treatment. **J. Immunol.**, 135: 2121-2127, 1985.
11. GROGAN, J.L.; KREMSNER, P.G.; VAN DAM, G.J. *et al.* - Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. **J. infect. Dis.**, 173: 1242-1247, 1996.
12. HASSAN, M.M.; BADAWI, M.A. & STRAND, M. - Circulating schistosomal antigen in diagnosis and assessment of cure in individuals infected with *Schistosoma mansoni*. **Amer. J. trop. Med. Hyg.**, 46: 737-744, 1992.
13. HILLYER, G.V. & GOMEZ DE RIOS, I. - The enzyme-linked immunosorbent assay (ELISA) for the immunodiagnosis of schistosomiasis. **Amer. J. trop. Med. Hyg.**, 28: 237-241, 1979.
14. HILLYER, G.V.; RUIZ-TIBEN, E.; KNIGHT, W.B.; GOMEZ de RIOS, I. & PELLEY, R.P. - Immunodiagnosis of infection with *Schistosoma mansoni*: comparison of ELISA, radioimmunoassay, and precipitation tests performed with antigens from eggs. **Amer. J. trop. Med. Hyg.**, 28: 661-669, 1979.
15. HILLYER, G.V.; NIEVES-FRAU, L.F. & VAZQUEZ, G. - Identification of a genus-specific *Schistosoma mansoni* soluble egg antigen reactive with the serum of infected patients. **Amer. J. trop. Med. Hyg.**, 35: 1198-1204, 1986.
16. HILLYER, G.V. & GALANES, M.S. - Seroepidemiology of schistosomiasis in Puerto Rico: evidence for vanishing endemicity. **Amer. J. trop. Med. Hyg.**, 60: 827-830, 1999.
17. IDRIS, M.A. & RUPPEL, A. - Diagnostic Mr 31/32,000 *Schistosoma mansoni* proteins (SM31/32): reactions with sera from Sudanese patients infected with *S. mansoni* or *S. haematobium*. **J. Helminth.**, 62: 95-101, 1988.
18. ISKANDER, R.; DAS, P.K. & AALBERSE, R.C. - IgG4 antibodies in Egyptian patients with schistosomiasis. **Int. Arch. Allergy**, 66: 200-207, 1981.
19. JASSIN, A.; HASSAN, K. & CATTY, D. - Antibody isotypes in human schistosomiasis mansoni. **Paras. Immunol.**, 9: 627-650, 1987.

20. KANAMURA, H.Y.; DIAS, L.C.S.; DA SILVA, R.M. *et al.* - A comparative epidemiologic study of specific antibodies (IgM and IgA) and parasitological findings in an endemic area of low transmission of *Schistosoma mansoni*. **Rev. Inst. Med. trop. S. Paulo**, 40: 85-91, 1998.
21. KATZ, N.; CHAVES, A. & PELLEGRINO, J. - A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. **Rev. Inst. Med. trop. S. Paulo**, 14: 397-400, 1972.
22. KIMURA, E.A.S. - *S. mansoni*: análise por "western-blot" dos antígenos envolvidos na resposta humoral de pacientes submetidos ao tratamento. São Paulo, 1986. [Master's Thesis - Instituto de Ciências Biomédicas da Universidade de São Paulo].
23. KLINKERT, M.Q.; BOMMERT, K.; MOSER, D. *et al.* - Immunological analysis of cloned *Schistosoma mansoni* antigens Sm31 and Sm32 with sera of schistosomiasis patients. **Trop. Med. Parasit.**, 42: 319-324, 1991.
24. LAEMMLI, U.K. - Cleavage of structural proteins during the assembly of the head of bacteriophage T4. **Nature (Lond.)**, 227: 680-685, 1970.
25. LOWRY, O.H.; ROSEBROUGH, N.J.; FARR, A.L. & RANDALL, R.J. - Protein measurement with the folin phenol reagent. **J. biol. Chem.**, 193: 265-275, 1951.
26. McLAREN, M.L.; LONG, E.G.; GOODGAME, R.W. & LILLYWHITE, J.E. - Application of the enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of *Schistosoma mansoni* infections in St. Lucia. **Trans. roy. Soc. trop. Med. Hyg.**, 73: 636-639, 1979.
27. McLAREN, M.L.; LILLYWHITE, J.E.; DUNNE, D.W. & DOENHOFF, M.J. - Serodiagnosis of human *Schistosoma mansoni* infections: enhanced sensitivity and specificity in ELISA using a fraction containing *S. mansoni* egg antigens ω_1 and α_1 . **Trans. roy. Soc. trop. Med. Hyg.**, 75: 72-79, 1981.
28. MOTT, K.E. & DIXON, H. - Collaborative study on antigens for immunodiagnosis of schistosomiasis. **Bull. Wld. Hlth. Org.**, 60: 729-753, 1982.
29. NASH, T.E. - Schistosomiasis and other trematode infections. In: ISSELBACKER, K.J. *et al.*, ed. **Harrison's principles of internal Medicine**. 13. ed. New York, Mc Graw Hill International, 1994. pt. 6, p. 924-931.
30. NOYA, O.; LOSADA, S.; ALARCÓN DE NOYA, B. *et al.* - Effect of chemotherapy on immune response to egg antigens of *Schistosoma mansoni* in chronically infected children from areas of low transmission. **Paras. Immunol.**, 17: 111-117, 1995.
31. OLIVER-GONZÁLEZ, J. - Anti-egg precipitins in sera of humans infected with *Schistosoma mansoni*. **J. infect. Dis.**, 95: 86-91, 1954.
32. PASSOS, A.D.C. & AMARAL, R.S. - Esquistossomose mansônica: aspectos epidemiológicos e de controle. **Rev. Soc. bras. Med. trop.**, 31(supl. 2): 61-74, 1998.
33. RAMÍREZ, R.M.; CEBALLOS, E.; ALARCÓN DE NOYA, B.; NOYA, O. & BIANCO, N. - The immunopathology of human schistosomiasis. III. Immunoglobulin isotype profiles and response to praziquantel. **Mem. Inst. Oswaldo Cruz**, 91: 593-599, 1996.
34. ROBERTS, S.M.; WILSON, R.A.; OUMA, J.H. *et al.* - Immunity after treatment of human schistosomiasis mansoni: quantitative and qualitative antibody responses to tegumental membrane antigens prepared from adult worms. **Trans. roy. Soc. trop. Med. Hyg.**, 81: 786-793, 1987.
35. RUPPEL, A.; DIESFELD, H.J. & ROTHER, U. - Immunoblot analysis of *Schistosoma mansoni* antigens with sera of schistosomiasis patients: diagnostic potential of an adult schistosome polypeptide. **Clin. exp. Immunol.**, 62: 499-506, 1985.
36. RUPPEL, A.; SHI, Y.E.; WEI, D.X. & DIESFELD, H.J. - Sera of *Schistosoma japonicum*-infected patients cross-react with diagnostic 31/32 kD proteins of *S. mansoni*. **Clin. exp. Immunol.**, 69: 291-298, 1987.
37. RUPPEL, A.; IDRIS, M.A.; SULAIMAN, S.M. & HILALI, A.M.H. - *Schistosoma mansoni* diagnostic antigens (Sm31/32): a sero-epidemiological study in the Sudan. **Trop. Med. Parasit.**, 41: 127-130, 1990.
38. RUPPEL, A.; XING, Y.; DELL, R.; NUMRICH, P. & SHI, Y.E. - *Schistosoma mansoni* and *S. japonicum*: decline of antibodies against diagnostic adult worm antigens (Sm31/32) following praziquantel treatment of mice. **Trop. Med. Parasit.**, 42: 325-331, 1991.
39. SILVA, L.C. da; HOSHINO-SHIMIZU, S.; KANAMURA, H. *et al.* - Serum antibody changes after chemotherapy of patients with schistosomiasis mansoni. A statistical analysis. **Rev. Inst. Med. trop. S. Paulo**, 17: 344-349, 1975.
40. SPENCER, L.; DE NOYA, B.A.; NOYA, O. & MASROUA, G. - Análisis comparativo entre la prueba de precipitación circunoval y ELISA con antígenos crudos para el diagnóstico de la esquistosomiasis en Venezuela. **G.E.N. (Caracas)**, 45: 77-83, 1991.
41. SOBH, M.A.; MOUSTAFA, F.E.; HAMED, S.M. & GHONEIM, M.A. - Infectious glomerulopathy induced by a defined agent (*Schistosoma mansoni*): progression despite early elimination of the causal agent. **Exp. Nephrol.**, 1: 261-264, 1993.
42. TANABE, M.; OKAZAKI, M.; OKAZAKI, M. *et al.* - Serological studies on schistosomiasis mansoni in the Northeast Brazil (I). **Rev. Inst. Med. Trop. S. Paulo**, 32: 121-131, 1990.
43. VALLI, L.C.; KANAMURA, H.Y.; DA SILVA, R.M.; RIBEIRO-RODRIGUES, R. & DIETZE, R. - Schistosomiasis mansoni: immunoblot analysis to diagnose and differentiate recent and chronic infection. **Amer. J. trop. Med. Hyg.**, 61: 302-307, 1999.
44. WORLD HEALTH ORGANIZATION - The control of schistosomiasis. **Wld. Hlth. Org. techn. Rep. Ser.**, (830), 1993.

Received: 22 December 2000

Accepted: 02 February 2001